tirzepatide surmount 4 for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Effect of Tirzepatide on Maintenance

The challenge is dealing with the hunger and cravings that can disrupt your momentum and leave you starting over every Monday

There is a broad consensus that GLP-1 receptor agonists have transformed the management of T2D, obesity, and related morbidity and have been associated with reduced progression of renal disease, cardiovascular disease, and mortality in people with metabolic disorders

Baseline lab work should include at minimum fasting glucose, HbA1c, lipid panel, comprehensive metabolic panel, and thyroid function

By promoting weight loss, semaglutide may help reduce the risk and severity of these obesity-related conditions, leading to improved overall health outcomes